AstraZeneca PLC: * IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC
* IMFINZI IMPROVED SURVIVAL & PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER IN ADRIATIC PHASE III TRIAL * SAFETY PROFILE FOR IMFINZI WAS CONSISTENT WITH ITS KNOWN PROFILE, AND NO NEW SAFETY SIGNALS WERE IDENTIFIED. Source text for Eikon: Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}